Class/mechanism: inhibits thrombin-related platelet aggregation.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
History of changes in FDA indication
- 2014-05: Initial approval for the reduction of thrombotic cardiovascular events in patients with prior MI or with PAD.
Also known as
- Brand name: Zontivity